Deng Guiming, Sun Hao, Huang Rong, Pan Hongming, Zuo Yanjiao, Zhao Ruihu, Du Zhongze, Xue Yingwei, Song Hongjiang
Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, China.
Front Oncol. 2023 Jul 20;13:1173266. doi: 10.3389/fonc.2023.1173266. eCollection 2023.
The development and advance of gastric cancer are inextricably linked to oxidative and antioxidant imbalance. Although immunotherapy has been shown to be clinically effective, the link between oxidative stress and gastric cancer patients treated with immune checkpoint inhibitor (ICIs) remains unknown. This study aims at looking into the prognostic value of oxidative stress scores in gastric cancer patients treated with ICIs.
By taking the propagation to receiver operating characteristic (ROC) we got the best cut-off values, and divided 265 patients receiving ICIs and chemotherapy into high and low GC-Integrated Oxidative Stress Score (GIOSS) groups. We also used Kaplan-Meier and COX regression models to investigate the relationship between oxidative stress biomarkers and prognosis.
Through both univariate and multivariate analyses, it's shown that GIOSS severs as an independent prognostic factor for progression-free survival (PFS) and Overall survival (OS). Based on GIOSS cutoff values, patients with high GIOSS levels, compared to those with low levels exhibited shorter PFS and OS, both in the high GIOSS group, which performed poorly in the ICIs subgroup and other subgroup analyses.
GIOSS is a biomarker that responds to systemic oxidative stress in the body and can predict prognosis in patients with gastric cancer who are taking ICIs. Additionally, it might come to medical professionals' aid in making more effective or more suitable treatment plans for gastric cancer.
胃癌的发展和进展与氧化和抗氧化失衡密切相关。尽管免疫疗法已被证明具有临床疗效，但氧化应激与接受免疫检查点抑制剂（ICI）治疗的胃癌患者之间的联系仍不清楚。本研究旨在探讨氧化应激评分在接受ICI治疗的胃癌患者中的预后价值。
通过将数据传播至受试者工作特征曲线（ROC）获得最佳临界值，将265例接受ICI和化疗的患者分为高和低胃癌综合氧化应激评分（GIOSS）组。我们还使用Kaplan-Meier和COX回归模型来研究氧化应激生物标志物与预后之间的关系。
通过单因素和多因素分析表明，GIOSS是无进展生存期（PFS）和总生存期（OS）的独立预后因素。基于GIOSS临界值，高GIOSS水平的患者与低水平患者相比，PFS和OS更短，在ICI亚组和其他亚组分析中，高GIOSS组的表现均较差。
GIOSS是一种反映体内全身氧化应激的生物标志物，可以预测接受ICI治疗的胃癌患者的预后。此外，它可能有助于医疗专业人员为胃癌制定更有效或更合适的治疗方案。
